GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allarity Therapeutics Inc (NAS:ALLR) » Definitions » Price-to-Owner-Earnings

Allarity Therapeutics (Allarity Therapeutics) Price-to-Owner-Earnings : (As of Jun. 10, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Allarity Therapeutics Price-to-Owner-Earnings?

As of today (2024-06-10), Allarity Therapeutics's share price is $0.4954. Allarity Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Allarity Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


ALLR's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.2
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-10), Allarity Therapeutics's share price is $0.4954. Allarity Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-587.57. Therefore, Allarity Therapeutics's PE Ratio for today is At Loss.

As of today (2024-06-10), Allarity Therapeutics's share price is $0.4954. Allarity Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-702.76. Therefore, Allarity Therapeutics's PE Ratio without NRI for today is At Loss.

During the past 5 years, Allarity Therapeutics's highest PE Ratio without NRI was 190.47. The lowest was 0.00. And the median was 0.00.


Allarity Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Allarity Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allarity Therapeutics Price-to-Owner-Earnings Chart

Allarity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - - -

Allarity Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Allarity Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Allarity Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allarity Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Allarity Therapeutics's Price-to-Owner-Earnings falls into.



Allarity Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Allarity Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.4954/-84.25
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allarity Therapeutics  (NAS:ALLR) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Allarity Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Allarity Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Allarity Therapeutics (Allarity Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
24 School Street, 2nd Floor, Boston, MA, USA
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improve clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
Executives
Laura Benjamin director 168 GOODRICH ST., LUNENBURG MA 01462
Joseph Walter Vazzano director 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Gerald W. Mclaughlin director 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
David Roth director C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joan Yvonne Brown officer: Chief Financial Officer C/O GOLDEN PHOENIX MINERALS, INC., 1675 EAST PRATER WAY, #102, SPARKS NV 89434
Steve Carchedi director, officer: Chief Executive Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Steen Knudsen officer: Chief Scientific Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Jens Erik Knudsen officer: Chief Financial Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Soren Gade Jensen director 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Duncan Moore director C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Thomas Jensen officer: SVP, Information Technology 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
James G. Cullem officer: SVP, Chief Business Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Marie Foegh officer: Chief Medical Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Sass & Larsen Aps 10 percent owner VESTERGARDSVEJ 6, GREVE G7 DK-2670
Leon Sass 10 percent owner JERNBAEK ALLE 5, HELSINGE G7 DK-3200

Allarity Therapeutics (Allarity Therapeutics) Headlines